MCID: ZKF001
MIFTS: 54

Zika Fever

Categories: Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Zika Fever

MalaCards integrated aliases for Zika Fever:

Name: Zika Fever 11 19 14 75
Zika Virus Infection 19 58 2 43 71 33
Zika Virus Disease 11 19 58 33
Zika Virus 75 41
Mosquito-Borne Viral Fever, Zika 33
Zika Virus Fever 33

Characteristics:


Prevelance:

Zika Virus Disease: 1-5/10000 (Brazil) 58

Age Of Onset:

Zika Virus Disease: All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Zika Fever

MedlinePlus: 41 Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pink eye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary: Zika Fever, also known as zika virus infection, is related to torch syndrome and st. louis encephalitis, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is DNAAF2 (Dynein Axonemal Assembly Factor 2), and among its related pathways/superpathways are SARS-CoV-2 Infection and NF-kappaB Signaling. The drugs Aluminum hydroxide and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and placenta, and related phenotypes are maculopapular exanthema and arthritis

GARD: 19 Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites. Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

Orphanet: 58 Zika virus disease is an emerging Aedes mosquito-born virus disease characterized by a clinical course that may be asymptomatic or mild with fever, conjunctivitis, muscle and joint pain, headache, exanthema, but may also be associated with severe neurological (meningitis, meningoencephalitis and myelitis) and auto-immune (Guillain-Barre syndrome) complications, as well as a potential increase of birth defects (microcephaly) if the infection occurs during pregnancy.

CDC: 2 Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Disease Ontology: 11 A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

Wikipedia 75 Zika fever: Zika fever, also known as Zika virus disease or simply Zika, is an infectious disease caused by the Zika... more...

Zika virus: Zika virus (ZIKV; pronounced /ˈziːkə/ or /ˈzɪkə/) is a member of the virus family Flaviviridae. It is... more...

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 492)
# Related Disease Score Top Affiliating Genes
1 torch syndrome 31.6 STAT2 IFNAR1
2 st. louis encephalitis 30.1 IFNA1 ERVW-1
3 acute retrobulbar neuritis 30.1 SH2D3A IFNB1
4 lymphocytic choriomeningitis 30.0 TYRO3 RIGI CD209 AXL
5 chikungunya 29.9 TLR3 RIGI FURIN CD209
6 yellow fever 29.8 RIGI IFNB1 IFNAR1
7 hantavirus pulmonary syndrome 29.8 RIGI IFNB1 ERVW-1
8 stomatitis 29.8 RIGI IFNB1 IFNA1
9 dengue virus 29.7 STAT2 RIGI CD209
10 viral encephalitis 29.7 TLR3 RIGI IFNB1 IFNAR1 IFNA1
11 encephalitis 29.7 TLR3 RIGI IFNB1 IFNA1 ERVW-1 CD209
12 middle east respiratory syndrome 29.6 SH2D3A IFNB1 FURIN
13 rubella 29.6 TLR3 RIGI IFNB1
14 west nile virus 29.6 RIGI IFNA1 CD209
15 vaccinia 29.6 STAT2 IFNB1 IFNA1 ERVW-1
16 poliomyelitis 29.6 TLR3 RIGI IFNB1 IFNA1
17 chickenpox 29.4 TLR3 IFNB1 IFNA1
18 crimean-congo hemorrhagic fever 29.2 IFNB1 IFNAR1 IFNA1 ERVW-1
19 tick-borne encephalitis 29.2 TLR3 SH2D3A IFNAR1 IFNA1 FURIN ERVW-1
20 mouth disease 29.2 TLR3 RIGI IFNA1 CD209
21 thrombocytopenia 29.2 STAT2 RIGI IFNB1 IFNA1 CD209
22 dengue disease 29.1 RIGI IFNB1 IFNAR1 IFNA1 FURIN ERVW-1
23 lassa fever 29.0 RIGI IFNB1 IFNAR1 IFNA1 ERVW-1 CD209
24 immune deficiency disease 29.0 IFNB1 IFNA1 FURIN ERVW-1 CD209
25 rabies 29.0 TLR3 STAT2 RIGI IFNA1
26 measles 29.0 TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
27 respiratory failure 28.9 TLR3 IFNB1 IFNA1 FURIN
28 influenza 28.8 TLR3 RIGI IFNB1 IFNA1 FURIN
29 dengue hemorrhagic fever 28.7 STAT2 RIGI IFNAR1 IFNA1 FURIN ERVW-1
30 multiple sclerosis 28.7 TLR3 IFNB1 IFNAR1 IFNA1 ERVW-1
31 severe acute respiratory syndrome 28.7 SH2D3A RIGI IFNB1 IFNA1 FURIN CD209
32 dengue shock syndrome 28.7 STAT2 RIGI IFNA1 FURIN ERVW-1 CD209
33 herpes simplex 28.7 TLR3 STAT2 RIGI IFNB1 IFNA1 CD209
34 mumps 28.6 TLR3 STAT2 IFNB1 IFNA1 FURIN
35 nervous system disease 28.6 TLR3 RIGI IFNB1 IFNAR1 IFNA1 AXL
36 west nile encephalitis 28.5 TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
37 avian influenza 28.4 TLR3 RIGI IFNB1 IFNA1 FURIN ERVW-1
38 west nile fever 28.3 TLR3 RIGI IFNB1 IFNAR1 IFNA1 FURIN
39 viral infectious disease 28.2 TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
40 ebola hemorrhagic fever 28.0 TLR3 SH2D3A RIGI IFNB1 IFNAR1 IFNA1
41 japanese encephalitis 27.7 TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
42 zika virus congenital syndrome 11.3
43 hydrocephalus, congenital, 1 10.7
44 distal arthrogryposis 10.5
45 hydrocephalus 10.4
46 cerebellar atrophy, developmental delay, and seizures 10.4
47 lissencephaly 10.4
48 neuroblastoma 10.4
49 toxoplasmosis 10.4
50 brain cancer 10.3

Graphical network of the top 20 diseases related to Zika Fever:



Diseases related to Zika Fever

Symptoms & Phenotypes for Zika Fever

Human phenotypes related to Zika Fever:

58 30 (show all 36)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 maculopapular exanthema 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0040186
2 arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001369
3 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
4 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
5 myalgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003326
6 conjunctivitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000509
7 headache 58 30 Frequent (33%) Frequent (79-30%)
HP:0002315
8 pruritus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000989
9 increased circulating igm level 58 30 Frequent (33%) Frequent (79-30%)
HP:0003496
10 abnormality of the cerebrospinal fluid 58 30 Frequent (33%) Frequent (79-30%)
HP:0002921
11 vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002013
12 edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000969
13 wrist swelling 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001225
14 ankle swelling 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001785
15 transient hearing impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012779
16 microcephaly 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000252
17 intrauterine growth retardation 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001511
18 thrombocytopenia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001873
19 lens subluxation 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001132
20 iris coloboma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000612
21 meningitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001287
22 subcutaneous hemorrhage 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001933
23 optic disc hypoplasia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007766
24 macular atrophy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007401
25 retinal pigment epithelial mottling 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007814
26 chorioretinal atrophy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000533
27 myelitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012486
28 acute demyelinating polyneuropathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0007131
29 absent foveal reflex 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030825
30 congenital intracerebral calcification 58 30 Very rare (1%) Very rare (<4-1%)
HP:0006906
31 infectious encephalitis 30 Very rare (1%) HP:0002383
32 abnormal optic disc morphology 30 Very rare (1%) HP:0012795
33 encephalitis 58 Very rare (<4-1%)
34 skin rash 58 Very frequent (99-80%)
35 spontaneous abortion 58 Very rare (<4-1%)
36 abnormality of the optic disc 58 Very rare (<4-1%)

Symptoms:

11
  • fever
  • rash
  • headaches
  • joint pain

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
2 Pharmaceutical Solutions Phase 2
3 Immunologic Factors Phase 2
4 Vaccines Phase 2
5
Aluminum sulfate Approved Phase 1 10043-01-3
6 Immunoglobulins, Intravenous Phase 1
7 Immunoglobulin G Phase 1
8 Antibodies, Blocking Phase 1
9 gamma-Globulins Phase 1
10 Rho(D) Immune Globulin Phase 1
11
Amphotericin B Approved, Investigational 1397-89-3 5280965
12
Streptomycin Approved, Vet_approved 57-92-1 19649
13
L-Glutamine Approved, Investigational, Nutraceutical 56-85-9 5961
14 Pyruvate
15 Penicillins
16 Gentamicins
17 Liposomal amphotericin B

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents Completed NCT03110770 Phase 2
3 A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas Active, not recruiting NCT04917861 Phase 2
4 A Phase 2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Day 1 and 29 and of a Single Booster Dose of PIZV Administered at 6 Months Post Dose 2 in Healthy Subjects Aged 18 to 65 Years in the US Not yet recruiting NCT05469802 Phase 2
5 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region Completed NCT03014089 Phase 1
6 Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area Completed NCT03008122 Phase 1
7 VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults Completed NCT02996461 Phase 1
8 Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers Completed NCT02996890 Phase 1
9 Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects Completed NCT02952833 Phase 1 Saline
10 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
11 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Completed NCT03343626 Phase 1 Placebo
12 Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate 2 Doses of 3 Sequentially Escalating Cohort of BBV121 in Healthy Adult Dengue Sero-Negative and Dengue Sero-Positive Volunteers Completed NCT04478656 Phase 1
13 Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP Completed NCT04033068 Phase 1
14 A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years Completed NCT03425149 Phase 1
15 Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers Completed NCT03624946 Phase 1
16 Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Completed NCT03611946 Phase 1
17 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Completed NCT04064905 Phase 1
18 A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults Completed NCT02937233 Phase 1
19 VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults Completed NCT02840487 Phase 1
20 Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers Completed NCT03443830 Phase 1 Tyzivumab
21 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers. Completed NCT04015648 Phase 1
22 Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) Recruiting NCT05123222 Phase 1
23 Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients Withdrawn NCT03776695 Phase 1
24 Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua Unknown status NCT04182685
25 Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome Unknown status NCT03227601
26 Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02810210
27 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Unknown status NCT03255369
28 Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy Unknown status NCT02943304
29 Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA Completed NCT03776903
30 Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome Completed NCT03330600
31 Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. Completed NCT03679728
32 Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil Completed NCT03106714
33 Persistence of Zika Virus in Semen After Acute Infection Completed NCT02733796
34 Rescuing Neurodevelopment in Zika-Exposed Infants in Grenada Completed NCT04697147
35 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
36 Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection Completed NCT02979938
37 Prospective Cohort Study of HIV and Zika in Infants and Pregnancy Completed NCT03263195
38 Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy Completed NCT03393286
39 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Completed NCT03631719
40 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
41 Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance) Completed NCT03188731
42 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
43 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
44 Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Completed NCT02916732
45 International Prospective Observational Cohort Study of Zika in Infants Completed NCT02856984
46 Pilot Study to Detect Zika Virus in Sperm Completed NCT02874456
47 The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy Completed NCT04118738
48 Adherence to Care for Children Born to Mothers With Laboratory Evidence of Confirmed or Possible Congenital Zika Virus Infection During Pregnancy. Recruiting NCT05041439
49 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose. Recruiting NCT01099852
50 Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome Enrolling by invitation NCT04398901

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Genetic Tests for Zika Fever

Anatomical Context for Zika Fever

Organs/tissues related to Zika Fever:

MalaCards : Brain, Eye, Placenta, Skin, Fetal Brain, T Cells, Whole Blood

Publications for Zika Fever

Articles related to Zika Fever:

(show top 50) (show all 7697)
# Title Authors PMID Year
1
Zika virus noncoding RNA cooperates with the viral protein NS5 to inhibit STAT1 phosphorylation and facilitate viral pathogenesis. 62 41
36449607 2022
2
Type I interferon receptor (IFNAR2) deficiency reveals Zika virus cytopathicity in human macrophages and microglia. 62 41
36439115 2022
3
In silico and in vitro arboviral MHC class I-restricted-epitope signatures reveal immunodominance and poor overlapping patterns. 41
36466864 2022
4
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies. 62
36411078 2023
5
Identification of an N-phenylsulfonyl-2-(piperazin-1-yl)methyl-benzonitrile derivative as Zika virus entry inhibitor. 62
36417826 2023
6
Methodological procedures explain observed differences in the competence of European populations of Aedes albopictus for the transmission of Zika virus. 62
36270381 2023
7
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. 62
36374844 2023
8
Sensitive Zika biomarker detection assisted by quantum dot-modified electrochemical immunosensing platform. 62
36371925 2023
9
3D Structural Analysis of Long Noncoding RNA by Small Angle X-ray Scattering and Computational Modeling. 62
36227567 2023
10
An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part I: Nanopore Sequencing of Infectious Agent Variants. 62
36301483 2023
11
A peptide derived from the N-terminal of NS2A for the preparation of ZIKV NS2A recognition polyclonal antibody. 62
36463933 2022
12
An update on teratogens for pediatric healthcare providers. 62
36081369 2022
13
Development and evaluation of a visible reverse transcription-loop-mediated isothermal amplification (RT-LAMP) for the detection of Asian lineage ZIKV in field-caught mosquitoes. 62
36103950 2022
14
Scramblases and virus infection. 62
36285664 2022
15
Role of Necroptosis in Central Nervous System Diseases. 62
36373337 2022
16
Emerging quinoline- and quinolone-based antibiotics in the light of epidemics. 62
35128812 2022
17
Recent trends and advancements in electrochemiluminescence biosensors for human virus detection. 62
35815064 2022
18
Transcriptional and post-transcriptional mechanisms that regulate the genetic program in Zika virus-infected macrophages. 62
36257579 2022
19
Influence of Zika virus 3'-end sequence and nonstructural protein evolution on the viral replication competence and virulence. 62
36149812 2022
20
Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E. 62
36274487 2022
21
Transcriptome profiling and Calreticulin expression in Zika virus -infected Aedes aegypti. 62
36473637 2022
22
GPI-anchored ligand-BioID2-tagging system identifies Galectin-1 mediating Zika virus entry. 62
36404916 2022
23
Immunological imbalance in microcephalic children with congenital Zika virus syndrome. 62
35857104 2022
24
Simultaneous exposure to both Zika virus and household insecticides during pregnancy, and fetal growth and infant developmental behavior outcomes at 18 months, in Guadeloupe. 62
36096163 2022
25
Identification and characterization of key residues in Zika virus envelope protein for virus assembly and entry. 62
35612559 2022
26
Neurological evaluation of microcephalic children with Zika syndrome and congenital cytomegalovirus infection. 62
36164338 2022
27
The RNA polymerase of cytoplasmically replicating Zika virus binds with chromatin DNA in nuclei and regulates host gene transcription. 62
36442102 2022
28
Zika virus infects human osteoclasts and blocks differentiation and bone resorption. 62
35670284 2022
29
Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5. 62
36055002 2022
30
Intrauterine Zika virus infection: review of the current findings with emphasis in the prenatal and postnatal brain imaging diagnostic methods. 62
33781162 2022
31
My child is growing and now? Exploring the environmental needs of children with congenital Zika syndrome according to their caregivers' perceptions. 62
36281641 2022
32
RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region. 62
36464077 2022
33
Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice. 62
36471432 2022
34
Multiplexed rapid antigen tests developed using multicolored nanoparticles and cross-reactive antibody pairs: Implications for pandemic preparedness. 62
36348742 2022
35
Re-emergence of dengue, chikungunya, and Zika viruses in 2021 after a 10-year gap in Gabon. 62
36200059 2022
36
Unraveling the Metabolic Alterations Induced by Zika Infection in Prostate Epithelial (PNT1a) and Adenocarcinoma (PC-3) Cell Lines. 62
36469742 2022
37
Aerosolized Zika virus infection in Guinea pigs. 62
36069671 2022
38
Spatial, Sociodemographic, and Weather Analysis of the Zika Virus Outbreak: U.S. Virgin Islands, January 2016-January 2018. 62
36399688 2022
39
Estimating Zika virus attack rates and risk of Zika virus-associated neurological complications in Colombian capital cities with a Bayesian model. 62
36465672 2022
40
Preclinical evaluation of [18F]FDG-PET as a biomarker of lymphoid tissue disease and inflammation in Zika virus infection. 62
35876869 2022
41
Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection. 62
35901544 2022
42
Offspring affected with in utero Zika virus infection retain molecular footprints in the bone marrow and blood cells. 62
36369716 2022
43
Zika Virus Infection Downregulates Connexin 43, Disrupts the Cardiomyocyte Gap Junctions and Induces Heart Diseases in A129 Mice. 62
36226984 2022
44
Folic acid-functionalized graphene quantum dots: Synthesis, characterization, radiolabeling with radium-223 and antiviral effect against Zika virus infection. 62
36154904 2022
45
Testosterone protects mice against zika virus infection and suppresses the inflammatory response in the brain. 62
36304103 2022
46
Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. 62
36383617 2022
47
Initial Recognition and Attachment of the Zika Virus to Host Cells: A Molecular Dynamics and Quantum Interaction Approach. 62
35951472 2022
48
Repeated Rapid Active Sampling Surveys Demonstrated a Rapidly Changing Zika Seroprevalence among Children in a Rural Dengue-endemic Region in Southwest Guatemala during the Zika Epidemic (2015-2016). 62
36252798 2022
49
Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. 62
36446201 2022
50
Arbovirus Antibody Seroprevalence in the Human Population from Cauca, Colombia. 62
36375460 2022

Variations for Zika Fever

Expression for Zika Fever

Search GEO for disease gene expression data for Zika Fever.

Pathways for Zika Fever

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 STAT2 RIGI IFNB1 IFNAR1 IFNA1 FURIN
2 12.33 TLR3 STAT2 RIGI IFNA1
3
Show member pathways
12.23 TLR3 STAT2 RIGI IFNB1 IFNAR1 IFNA1
4
Show member pathways
12.16 TLR3 RIGI IFNB1 IFNA1
5
Show member pathways
12.14 STAT2 RIGI IFNB1 IFNAR1 IFNA1
6
Show member pathways
12.1 TLR3 RIGI IFNB1 IFNA1
7 11.73 TYRO3 RIGI CD209 AXL
8 11.67 STAT2 IFNAR1 FURIN
9 11.42 STAT2 IFNB1 IFNAR1 IFNA1
10 11.25 IFNB1 RIGI STAT2
11
Show member pathways
11 TLR3 STAT2 RIGI IFNB1 IFNAR1
12 10.88 STAT2 IFNAR1
13 10.73 RIGI IFNB1
14 10.46 TLR3 RIGI

GO Terms for Zika Fever

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 10.15 STAT2 IFNB1 IFNAR1 IFNA1
2 defense response to virus GO:0051607 10.1 IFNA1 IFNB1 RIGI STAT2 TLR3
3 response to virus GO:0009615 10.04 TLR3 RIGI IFNB1 IFNAR1
4 receptor signaling pathway via JAK-STAT GO:0007259 10 IFNAR1 IFNB1 STAT2
5 cellular response to virus GO:0098586 9.97 TLR3 IFNB1 IFNAR1 IFNA1
6 cellular response to interferon-alpha GO:0035457 9.88 IFNAR1 AXL
7 defense response GO:0006952 9.88 TLR3 STAT2 IFNB1 IFNA1
8 vagina development GO:0060068 9.87 TYRO3 AXL
9 ovulation cycle GO:0042698 9.86 TYRO3 AXL
10 detection of virus GO:0009597 9.84 TLR3 RIGI
11 cellular response to exogenous dsRNA GO:0071360 9.8 TLR3 RIGI IFNB1
12 negative regulation of lymphocyte activation GO:0051250 9.76 TYRO3 AXL
13 type I interferon-mediated signaling pathway GO:0060337 9.76 STAT2 IFNB1 IFNAR1 IFNA1
14 forebrain cell migration GO:0021885 9.73 TYRO3 AXL
15 secretion by cell GO:0032940 9.73 AXL FURIN TYRO3
16 response to exogenous dsRNA GO:0043330 9.56 TLR3 RIGI IFNB1 IFNA1
17 lymphocyte activation GO:0046649 9.51 TYRO3 AXL
18 positive regulation of viral life cycle GO:1903902 9.1 TYRO3 CD209 AXL

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.1 TYRO3 CD209 AXL

Sources for Zika Fever

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....